ImmuPharma PLC (LON:IMM) said the six months ended June has been a period of immense progress for the company and its lead drug Lupuzor, for the auto-immune disease lupus.
Lupuzor is currently undergoing a phase III clinical trial 200 in patients in the US, Europe and Mauritius – with 26% of the group having completed the 12-month course of treatment and everybody having passed the six-month milestone.
READ: Immupharma starts preparations for Lupuzor submission as trial makes good progress
Top line results from the study are due in the first-quarter of next year, while the firm said Tuesday it has initiated the first steps in the regulatory submissions process.
The company spent £2.3mln on research and development, while the loss for the period was £3mln (down from £3.7mln on the same period last year).
Having raised £4.1mln of fresh funds in March, ImmuPharma was sitting on £3.13mln as at June 30.
READ: ImmuPharma says more than a quarter of patients have now completed phase III lupus trial
“The board would like to thank its shareholders for their continued support, as well as its staff, corporate and scientific advisors and the CNRS for their ongoing collaboration," said chairman Tim McCarthy.
The CNRS, or the Centre National de la Recherche Scientifique, is France’s preeminent drugs research group and the company’s long-standing partner.